Faecal calprotectin, lactoferrin, M2-pyruvate kinase and S100A12 in severe ulcerative colitis: a prospective multicentre comparison of predicting outcomes and monitoring response

被引:103
作者
Turner, D. [1 ]
Leach, S. T. [3 ]
Mack, D. [4 ]
Uusoue, K. [2 ]
McLernon, R. [2 ]
Hyams, J. [5 ]
Leleiko, N. [6 ]
Walters, T. D. [2 ]
Crandall, W. [7 ]
Markowitz, J. [8 ]
Otley, A. R. [9 ]
Griffiths, A. M. [2 ]
Day, A. S. [3 ]
机构
[1] Hebrew Univ Jerusalem, Shaare Zedek Med Ctr, Paediat Gastroenterol & Nutr Unit, IL-91031 Jerusalem, Israel
[2] Hosp Sick Children, Toronto, ON M5G 1X8, Canada
[3] Univ New S Wales, Sch Womens & Childrens Hlth, Sydney, NSW, Australia
[4] Childrens Hosp Eastern Ontario, Ottawa, ON K1H 8L1, Canada
[5] Univ Connecticut, Sch Med, Connecticut Childrens Med Ctr, Hartford, CT 06112 USA
[6] Brown Univ, Providence, RI 02912 USA
[7] Ohio State Univ, Nationwide Childrens Hosp, Columbus, OH 43210 USA
[8] Schneiders Childrens Hosp, Long Isl City, NY USA
[9] IWK Hosp, Halifax, NS, Canada
关键词
INFLAMMATORY-BOWEL-DISEASE; INTESTINAL INFLAMMATION; NONINVASIVE MARKERS; PYRUVATE-KINASE; ACTIVITY INDEX; CLINICAL-COURSE; CHILDREN; RELAPSE; PRECISION; THERAPY;
D O I
10.1136/gut.2010.211755
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Objective To compare four faecal markers for their ability to predict steroid refractoriness in severe paediatric ulcerative colitis (UC). Construct validity and responsiveness to change were also assessed. Methods This was a prospective multicentre cohort study. Stool samples from 101 children (13.3 +/- 3.6 years; Pediatric UC Activity Index (PUCAI) at admission 72 +/- 12 points) were obtained at the third day of intravenous steroid therapy. Repeated samples at discharge were obtained from 24 children. Predictive validity was assessed using diagnostic utility statistics to predict steroid failure (ie, the need for salvage treatment). Concurrent validity was assessed using correlational analysis with the following constructs: PUCAI, Lindgren and Seo scores, physician's global assessment, albumin, erythrocyte sedimentation rate and C-reactive protein (CRP). Responsiveness was assessed using test utility and correlational strategies. Results Median values (IQR) were very high at baseline for all four markers (calprotectin 4215 mu g/g (2297-8808); lactoferrin 212 mg/g (114-328); M2-pyruvate kinase (M2-PK) 363 U/g (119-3104); and S100A12 469 mg/g (193-1112)). M2-PK was numerically superior to the other three markers and CRP in predicting response to corticosteroid treatment (area under the receiver operating characteristic (ROC) curve 0.75 (95% CI 0.64 to 0.85; p<0.001) vs <0.65 for the others). However, it did not add to the predictive ability of the PUCAI (area under the ROC 0.81 (95% CI 0.73 to 0.89)). M2-PK also had the highest construct validity but with a modest mean correlation with all constructs (r=0.3; p<0.05). None of the markers was responsive to change (Spearman's rho correlation with change in the PUCAI <0.1; p>0.05, area under the ROC curve <0.65; p>0.05). Conclusions The four markers were greatly elevated in severe paediatric UC. Only M2-PK had good construct and predictive validity, and none was responsive to change. The PUCAI, a simple clinical index, performed better than the faecal markers in predicting outcome following a course of intravenous corticosteroids in severe UC.
引用
收藏
页码:1207 / 1212
页数:6
相关论文
共 46 条
[1]  
[Anonymous], 2007, J PEDIATR GASTR NUTR, V44, P653
[2]   Understanding the relevance of measured change through studies of responsiveness [J].
Beaton, DE .
SPINE, 2000, 25 (24) :3192-3199
[3]   Fecal lactoferrin: A new parameter to monitor infliximab therapy [J].
Buderus, S ;
Boone, J ;
Lyerly, D ;
Lentze, MJ .
DIGESTIVE DISEASES AND SCIENCES, 2004, 49 (06) :1036-1039
[4]   Faecal calprotectin as reliable non-invasive marker to assess the severity of mucosal inflammation in children with inflammatory bowel disease [J].
Canani, R. Berni ;
Terrin, G. ;
Rapacciuolo, L. ;
Miele, E. ;
Siani, M. C. ;
Puzone, C. ;
Cosenza, L. ;
Staiano, A. ;
Troncone, R. .
DIGESTIVE AND LIVER DISEASE, 2008, 40 (07) :547-553
[5]   Pyruvate kinase M2 is a phosphotyrosine-binding protein [J].
Christofk, Heather R. ;
Vander Heiden, Matthew G. ;
Wu, Ning ;
Asara, John M. ;
Cantley, Lewis C. .
NATURE, 2008, 452 (7184) :181-U27
[6]   Fecal M2-pyruvate kinase (M2-PK): A novel marker of intestinal inflammation [J].
Chung-Faye, Guy ;
Hayee, Bu'Hussain ;
Maestranzi, Susan ;
Donaldson, Nora ;
Forgacs, Ian ;
Sherwood, Roy .
INFLAMMATORY BOWEL DISEASES, 2007, 13 (11) :1374-1378
[7]   Calprotectin is a stronger predictive marker of relapse in ulcerative colitis than in Crohn's disease [J].
Costa, F ;
Mumolo, MG ;
Ceccarelli, L ;
Bellini, M ;
Romano, MR ;
Sterpi, C ;
Ricchiuti, A ;
Marchi, S ;
Bottai, M .
GUT, 2005, 54 (03) :364-368
[8]   Fecal pyruvate kinase: A potential new marker for intestinal inflammation in children with inflammatory bowel disease [J].
Czub, Elzbieta ;
Herzig, Karl-Heinz ;
Szaflarska-Poplawska, Anna ;
Kiehne, Karlheinz ;
Socha, Piotr ;
Wos, Halina ;
Kaminska, Barbara ;
Blaszczynski, Michal ;
Cichy, Wojciech ;
Bala, Grazyna ;
Brodzicki, Jacek ;
Grzybowska-Chlebowczyk, Urszula ;
Walkowiak, Jaroslaw .
SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, 2007, 42 (10) :1147-1150
[9]   Can calprotectin predict relapse risk in inflammatory bowel disease? [J].
D'Inca, Renata ;
Dal Pont, Elisabetta ;
Di Leo, Vincenza ;
Benazzato, Luca ;
Martinato, Matteo ;
Lamboglia, Francesca ;
Oliva, Lydia ;
Sturniolo, Giacomo Carlo .
AMERICAN JOURNAL OF GASTROENTEROLOGY, 2008, 103 (08) :2007-2014
[10]   Fecal S100A12: A novel noninvasive marker in children with Crohn's disease [J].
de Jong, Naomi S. H. ;
Leach, Steven T. ;
Day, Andrew S. .
INFLAMMATORY BOWEL DISEASES, 2006, 12 (07) :566-572